X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
PAX-101, if approved by the FDA will be the potential first and only intravenous form of suramin for the treatment of Stage 1 Human African Trypanosomiasis (HAT), caused by Trypanosoma brucei rhodesiense.
Lead Product(s): Suramin
Therapeutic Area: Infections and Infectious Diseases Product Name: PAX-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
The Company intends to use the net proceeds to advance the Company's development programs, including PAX-101 (suramin sodium), an antipurinergic agent delivered as an IV infusion.
Lead Product(s): Suramin
Therapeutic Area: Neurology Product Name: PAX-101
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $7.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 22, 2023
Details:
Through the acquisition, PaxMedica gains certain suramin research assets to support the submission for the approval of PAX-101 (suramin sodium), specifically for the treatment of African Sleeping Sickness caused by the Trypanosoma brucei rhodesiense parasite.
Lead Product(s): Suramin
Therapeutic Area: Infections and Infectious Diseases Product Name: PAX-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: PaxMedica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 31, 2023
Details:
PAX-101 (suramin sodium) is a intravenous formulation for Autism Spectrum Disorder. Suramin is a broadly acting anti-purinergic therapy and has reported positive results from a dose range study.
Lead Product(s): Suramin
Therapeutic Area: Rare Diseases and Disorders Product Name: PAX-101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2023
Details:
Under the agreement, VoxNova will have exclusive access to PaxMedica’s PAX-101 intravenous suramin for the treatment of Autism Spectrum Disorder, in the United States for a period of up to seven years.
Lead Product(s): Suramin
Therapeutic Area: Neurology Product Name: PAX-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Vox Nova
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 06, 2023
Details:
PAX-101 (suramin sodium) is a intravenous formulation for Autism Spectrum Disorder. Suramin is a broadly acting anti-purinergic therapy and has reported positive results from a dose range study.
Lead Product(s): Suramin
Therapeutic Area: Neurology Product Name: PAX-101
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Details:
PAX-101 (IV Suramin) is a broadly acting anti-purinergic therapy and has reported positive results from a dose range study and completed a Phase 2B study for ASD in 2021.
Lead Product(s): Suramin
Therapeutic Area: Neurology Product Name: PAX-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
PaxMedica will use the net proceeds for the development of the autism spectrum disorder (ASD) indication for PAX-101. Suramin is a broadly acting anti-purinergic therapy and has reported positive results from a dose range study.
Lead Product(s): Suramin
Therapeutic Area: Neurology Product Name: PAX-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lind Global Partners
Deal Size: $3.2 million Upfront Cash: Undisclosed
Deal Type: Financing February 03, 2023
Details:
PAX-101 (suramin) Phase 1B Study has been approved by SAHPRA for individuals with documented COVID-19 infections who develop debilitating physical and neuropsychiatric symptoms that persist for more than 12 weeks after the viral infection has passed.
Lead Product(s): Suramin
Therapeutic Area: Infections and Infectious Diseases Product Name: PAX-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2022
Details:
FDA Approval of PAX-101 in HAT could qualify for New Chemical Entity exclusivity, in addition to Orphan Drug exclusivity, and could also result in PaxMedica being awarded a Priority Review Voucher (PRV) under the FDA’s Tropical Disease Priority Review Voucher Program.
Lead Product(s): Suramin
Therapeutic Area: Infections and Infectious Diseases Product Name: PAX-101
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021
Details:
RLS will use the proceeds to fund a Phase 2 trial of suramin in diuretic resistant Acute Kidney Injury (AKI).
Lead Product(s): Suramin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: REX Health Ventures
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
